Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
XBIT
SellSinkerXBiotech Inc. · Healthcare · United States · $69M · Avg Vol: $93K/d
27
StockRankGet insider-trade alerts
Q
37
V
36
M
43
P/E (TTM)
—
ROE
-29.9%
D/E
0.0x
Dividend %
—
COMPANY DESCRIPTION
XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious diseases.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM |
|---|---|---|---|---|---|---|
| Revenue | 4.0M | 0 | 0 | 0 | — | — |
| EPS | -1.08 | -0.81 | -1.26 | -1.49 | — | -1.48 |
| Shares | 30.4M | 30.4M | 30.5M | 30.5M | +0.2% | 30.5M |
| Debt | — | — | 10.3M | — | — | — |
| Equity | 240.4M | 218.8M | 182.3M | 140.3M | -16.4% | — |
| Op CF | -14.8M | -18.7M | -31.0M | -39.9M | — | -40.7M |
| Inv CF | -63.9M | 61.5M | -1.3M | -0.3M | — | — |
| Fin CF | 0 | -9.0K | 10.4M | -10.3M | — | — |
Loading 1Y...
PRICE (1Y)-3.1%
SMA 50SMA 200
Close
$2.17
RSI (14)
26.7
52W High
$3.44
From 52W High
0.6%
SCORE BREAKDOWN
Quality
37
ROIC
-28.1%25.7
ROE
-29.9%25.3
GP/Assets
—N/A
Op. Margin
0.0%38.1
FCF/Assets
-26.8%15.9
Piotroski
324.5
Int. Cover
—N/A
D/E Ratio
0.00x98.1
Current Ratio
33.15x98.4
Value
36
P/E (TTM)
—N/A
EV/EBITDA
0.9x25.0
P/FCF
—N/A
P/B
0.5x96.6
P/S
—N/A
Div Yield
—N/A
Momentum
43
52W High %
63%40.8
RS 6M
-20%41.0
SMA 50/200
0.96x44.7
EPS Rev 4W
0.0%34.4
EPS Rev 12W
—N/A
EPS Improve
+109%76.4
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$69M
P/E (Forward)
16.9x
Gross Margin
—
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of XBIT are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| XBIT | XBiotech Inc.(you) | $69M | 27 | Sell |
| CSBR | Champions Oncology, Inc. | $68M | 30 | Sell |
| APLM | Apollomics, Inc. | $77M | 28 | Sell |
| RNXT | RenovoRx, Inc. | $75M | 26 | Sell |
| INMB | INmune Bio Inc. | $65M | 31 | Sell |
| MNOV | MediciNova, Inc. | $71M | 23 | Sell |
| ACRV | Acrivon Therapeutics, Inc. | $88M | 29 | Sell |
| PTHS | Pelthos Therapeutics Inc. | $95M | 26 | Sell |
| ACET | Adicet Bio, Inc. | $85M | 23 | Sell |
| PMVP | PMV Pharmaceuticals, Inc. | $65M | 19 | Strong Sell |
Peer medians: ROE -30.7% · P/E 27.0x · Gross margin 58.3%